Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: A single-center study

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages 942-948

  Friedel, Godehard ^a   Budach, Wilfried ^a   Dippon, Juergen ^a   Spengler, Werner ^a   Eschmann, Susanne Martina ^a   Pfannenberg, Christina ^a   Al Kamash, Fawaz ^a   Walles, Thorsten ^a   Aebert, Hermann ^a   Kyriss, Thomas ^a   Veit, Stefanie ^a   Kimmich, Martin ^a   Bamberg, Michael ^a   Kohlhaeufl, Martin ^a   Steger, Volker ^a   Hehr, Thomas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MORBIDITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY; ADJUVANT THERAPY; ADOLESCENT; CLINICAL TRIAL; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION DOSE FRACTIONATION; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; THORACOTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949880031     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.7810     Document Type: Article

References (29)

1. Friedel G, Hruska D, Budach W, et al: Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. Lung Cancer 30:175-185, 2000 (Pubitemid 32007874)
2. Green MR, Cox JD, Ardizzoni A, et al: Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): A consensus report. Lung Cancer 11:S11-S13, 1994 (suppl 3)
3. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
4. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
5. Friedel G, Linder A, Weigang S, et al: The surgical treatment of stage III (N2), in Campagno F, De Lena M (eds): Recent Advances in Lung Cancer. Milan, Italy, Masson, 1995, pp 119-127
6. Hata E, Miyamoto H, Tanaka M, et al: The necessity of extended systemic dissection of the regional lymph node in radical operation for lung cancer [in Japanese]. Kyobu Geka 47:40-44, 1994
7. Detterbeck F, Kiser A, Detterbeck FC, et al: anonymous diagnosis and treatmnent of lung cancer, in Detterbeck FC, Rivera MP, Siocinski MA, et al (eds): An Evidence-Based Guide for Practicing Clinicians. Philadelphia, PA, Saunders, 2001
8. Eschmann SM, Friedel G, Paulsen F, et al: FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 29:804-808, 2002
9. Hurtgen M, Metzler B, Friedel G, et al: Mediastinoscopic ultrasonography (MUS). Eur J Cardiothorac Surg 26:842-844, 2004 (Pubitemid 39273597)
10. Wagner H Jr, Lad T, Piantadosi S, et al: Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881. Chest 106:348S-354S, 1994 (suppl)
11. van Rens MT, de la Riviere AB, Elbers HR, et al: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374-379, 2000 (Pubitemid 30111585)
12. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al: Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases - Leuven Lung Cancer Group. Ann Thorac Surg 63:1441-1450, 1997 (Pubitemid 27239740)
13. van Meerbeeck JP, Kramer GW, Van Schil PE, et al: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442-450, 2007 (Pubitemid 47073567)
14. Albain KS, Swann RS, Rusch VR, et al: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 23:624s, 2005 (suppl; abstr 7014)
15. Eberhardt W, Wilke H, Stamatis G, et al: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial. J Clin Oncol 16:622-634, 1998 (Pubitemid 28135609)
16. Belani CP, Wang W, Johnson DH, et al: Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760-3767, 2005
17. Thomas M, Rube C, Semik M, et al: Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 17:1185, 1999
18. Stamatis G, Eberhardt W, Stuben G, et al: Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: Long-term results. Ann Thorac Surg 68:1144-1149, 1999
19. Caglar HB, Baldini EH, Othus M, et al: Outcomes of patients with stage III non-small-cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115:4156-4166, 2009
20. Friedel G, Graeter T, Haas V, et al: Quality assurance in Thoracic Surgery considering procedures because of lung cancer: A pilot study [in German]. Thoracic Surg Sci 1:Doc02, 2004
21. Birkmeyer JD, Siewers AE, Finlayson EV, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137, 2002 (Pubitemid 34984604)
22. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995
23. Choi NC, Carey RW, Daly W, et al: Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15:712-722, 1997 (Pubitemid 27074241)
24. Eberhardt WE, Albain KS, Pass H, et al: Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 42:S9-S14, 2003 (suppl 1) (Pubitemid 37383737)
25. Allen AM, Mentzer SJ, Yeap BY, et al: Pneumonectomy after chemoradiation: The Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112:1106-1113, 2008 (Pubitemid 351304596)
26. Machtay M, Lee JH, Stevenson JP, et al: Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: Long-term results and associations with pathologic response. J Thorac Cardiovasc Surg 127:108-113, 2004 (Pubitemid 38160473)
27. Bedini AV, Tavecchio L, Palazzi M: Surgical results of maximal local-regional treatment (cisplatin-enhanced high-dose radiotherapy and adjuvant surgery) in initially non-resectable stage III lung cancer. Lung Cancer 35:271-277, 2002 (Pubitemid 34158660)
28. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891, 2005
29. Steger V, Walles T, Kosan B, et al: Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: Mid-term results and indicators for survival. Ann Thorac Surg 87:1676-1683, 2009